M42 Group CEO Dimitris Moulavasilis discusses how the Abu Dhabi-based healthcare company is combining artificial intelligence, genomics and clinical services to reshape healthcare. He explores the group’s international expansion, the Emirati Genome Programme and the potential for technology to help doctors identify health risks earlier and move healthcare towards prevention rather than treatment.Read More
M42 CEO on AI, genomics and the future of healthcare
By @dan_murphy
